Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) |
Viberzi is owned by Abbvie.
Viberzi contains Eluxadoline.
Viberzi has a total of 20 drug patents out of which 0 drug patents have expired.
Viberzi was authorised for market use on 27 May, 2015.
Viberzi is available in tablet;oral dosage forms.
Viberzi can be used as treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food.
Drug patent challenges can be filed against Viberzi from 28 May, 2019.
The generics of Viberzi are possible to be released after 14 March, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-...
Dosage: TABLET;ORAL